IF: 0.587
Cite Score:
0.7
THOMSON REUTERS - SCOPUS

Successful Treatment of Congenital Chyloperitoneum with Platelet-Rich Fibrin Glue

AUTHORS

Marjan Joudi 1 , Daryoush Hamidi Alamdari 2 , * , Hamid-Reza Rahimi 3

How to Cite: Joudi M, Hamidi Alamdari D, Rahimi H. Successful Treatment of Congenital Chyloperitoneum with Platelet-Rich Fibrin Glue, Iran J Pediatr. 2013 ; 23(3):357-359.

ARTICLE INFORMATION

Iranian Journal of Pediatrics: 23 (3); 357-359
Published Online: December 28, 2012
Article Type: Case Report
Received: November 24, 2011
Accepted: July 23, 2012

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Congenital chyloperitoneum is an uncommon clinical condition. A few cases of congenital chyloperitoneum in children have been described who were treated in a variety of methods.
Case Presentation: Congenital chyloperito was diagnosed in a 5-day-old baby boy with a significant abdominal distension. Due to the failed conservative managements by medium-chain triglycerides (MCT) enriched milk and partial parenteral nutrition (PPN), the authors tried platelet rich fibrin glue (PRFG) as an alternative choice which was applied through an already inserted intra-abdominal catheter. PRFG successfully stopped the lymph leakage from all over the small intestinal mesentery;  thereby PRFG may be considered as an effective alternative treatment before surgical intervention.
Conclusion: Applying PRFG is an easy, safe, and effective alternative option that may be used to close the chylous ascites lymph leakage in children if conservative management with PPN fails.

 

Keywords

Chyloperitoneum Platelets Fibrin Glue Congenital

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

References

  • 1.

    References are available on the PDF.

  • COMMENTS

    LEAVE A COMMENT HERE: